Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
Stephanie M Kaiser, Sruthi Arepalli, Justis P Ehlers Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USACorrespondence: Justis P EhlersCole Eye Institute, Cleveland Clinic, Cleveland, OH, USAEmail ehlersj@ccf.orgAbstract: Age-related macular degeneration (AMD) is the most common cause of legal...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-09-01
|
| Series: | Journal of Experimental Pharmacology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/current-and-future-anti-vegf-agents-for-neovascular-age-related-macula-peer-reviewed-fulltext-article-JEP |
| _version_ | 1818436310842474496 |
|---|---|
| author | Kaiser SM Arepalli S Ehlers JP |
| author_facet | Kaiser SM Arepalli S Ehlers JP |
| author_sort | Kaiser SM |
| collection | DOAJ |
| description | Stephanie M Kaiser, Sruthi Arepalli, Justis P Ehlers Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USACorrespondence: Justis P EhlersCole Eye Institute, Cleveland Clinic, Cleveland, OH, USAEmail ehlersj@ccf.orgAbstract: Age-related macular degeneration (AMD) is the most common cause of legal blindness in developed countries. Neovascular (ie, wet) AMD is currently managed with intravitreal therapy. Traditional treatments (ie, bevacizumab, ranibizumab, aflibercept) provide high-efficacy therapy but can also require frequent dosing. Newer and future anti-VEGF therapies aim to decrease injection frequency through eitherlonger half life or port-delivery systems (brolucizumab, conbercept, KSI-301, ranibizumab). This review outlines current anti-VEGF treatments and ways by which their duration might be extended.Keywords: anti-VEGF, wet age-related macular degeneration, brolucizumab, aflibercept, bevacizumab, ranibizumab, KSI-301 |
| first_indexed | 2024-12-14T17:06:45Z |
| format | Article |
| id | doaj.art-0378c9dd645744f793536061f4514689 |
| institution | Directory Open Access Journal |
| issn | 1179-1454 |
| language | English |
| last_indexed | 2024-12-14T17:06:45Z |
| publishDate | 2021-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Experimental Pharmacology |
| spelling | doaj.art-0378c9dd645744f793536061f45146892022-12-21T22:53:42ZengDove Medical PressJournal of Experimental Pharmacology1179-14542021-09-01Volume 1390591269273Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular DegenerationKaiser SMArepalli SEhlers JPStephanie M Kaiser, Sruthi Arepalli, Justis P Ehlers Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USACorrespondence: Justis P EhlersCole Eye Institute, Cleveland Clinic, Cleveland, OH, USAEmail ehlersj@ccf.orgAbstract: Age-related macular degeneration (AMD) is the most common cause of legal blindness in developed countries. Neovascular (ie, wet) AMD is currently managed with intravitreal therapy. Traditional treatments (ie, bevacizumab, ranibizumab, aflibercept) provide high-efficacy therapy but can also require frequent dosing. Newer and future anti-VEGF therapies aim to decrease injection frequency through eitherlonger half life or port-delivery systems (brolucizumab, conbercept, KSI-301, ranibizumab). This review outlines current anti-VEGF treatments and ways by which their duration might be extended.Keywords: anti-VEGF, wet age-related macular degeneration, brolucizumab, aflibercept, bevacizumab, ranibizumab, KSI-301https://www.dovepress.com/current-and-future-anti-vegf-agents-for-neovascular-age-related-macula-peer-reviewed-fulltext-article-JEPanti-vegfwet age-related macular degenerationbrolucizumabafliberceptbevacizumabranibizumabksi-301 |
| spellingShingle | Kaiser SM Arepalli S Ehlers JP Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration Journal of Experimental Pharmacology anti-vegf wet age-related macular degeneration brolucizumab aflibercept bevacizumab ranibizumab ksi-301 |
| title | Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration |
| title_full | Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration |
| title_fullStr | Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration |
| title_full_unstemmed | Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration |
| title_short | Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration |
| title_sort | current and future anti vegf agents for neovascular age related macular degeneration |
| topic | anti-vegf wet age-related macular degeneration brolucizumab aflibercept bevacizumab ranibizumab ksi-301 |
| url | https://www.dovepress.com/current-and-future-anti-vegf-agents-for-neovascular-age-related-macula-peer-reviewed-fulltext-article-JEP |
| work_keys_str_mv | AT kaisersm currentandfutureantivegfagentsforneovascularagerelatedmaculardegeneration AT arepallis currentandfutureantivegfagentsforneovascularagerelatedmaculardegeneration AT ehlersjp currentandfutureantivegfagentsforneovascularagerelatedmaculardegeneration |